ClinicalTrials.gg
RecruitingNCT05392764EMPA-AHFUpdated Feb 13, 2026

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

A Phase 3 interventional study of Empagliflozin 10 MG and Placebo in Acute Heart Failure, sponsored by Juntendo University. Recruiting at 69 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Juntendo University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Planned enrollment
8th of 51
444 · median 90
Started
2022
with 9 others
Phase 3
14 of 51
5 open now
Primary completion
2026-12
later than 12 of 21 live
Registered
23rd of 51
by date

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 8th largest by planned enrollment, is one of 10 that started in 2022, is one of 14 in phase 3, reaches primary completion later than 12 of the 21 other live ones, and was the 23rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who meet the below inclusion criteria will be randomized within 12 h after presentation to the hospital

  1. Age of ≥20*
  2. Hospitalized with a diagnosis of acute heart failure, requiring intravenous loop diuretic therapy, and with all of the following characteristics:

    i. Dyspnoea at rest or induced by slight exertion ii. At least two of the following findings: jugular venous distention, pulmonary rales, lower leg edema, and pulmonary congestion on chest X-ray iii. If the patient has a sinus rhythm at the time of admission, BNP ≥350 pg/mL or NT-proBNP ≥1400 pg/mL; if the patient has atrial fibrillation at the time of admission, BNP ≥500 pg/mL or NT-proBNP ≥2000 pg/mL. For patients taking an angiotensin receptor neprilysin inhibitor, only the reference value for NT-proBNP will be applicable.

  3. At least one of the following characteristics:

    i. \<60 mL/min/1.73m2, as calculated using the CKD Epidemiology Collaboration for JapaneseModification of Diet in Renal Disease formula ii. Already taking ≥40 mg of oral furosemide during the period before hospitalization. For patients on loop diuretics other than furosemide, the following conversion should be used: oral furosemide 20 mg = oral azosemide 30 mg = oral torasemide 5 mg.

    iii. Urine output of \<300 mL during the 2 h following an appropriate dose of intravenous furosemide administered after hospitalization. An appropriate dose of intravenous furosemide is 20 mg for patients who have not been taking furosemide regularly before hospitalization and is the same as, or greater than, the daily oral dose for patients who have been taking furosemide regularly before hospitalization.

  4. Provided written consent to participate in the study *If the patient is 90 years of age or older and cognitive decline is considered necessary, Mini-Cog should be used to confirm that its score is not less than 3.

Exclusion criteria

Exclusion Criteria:

  1. \<20 mL/min/1.73m2 at the time of admission
  2. Already taking an SGLT2i within 3 months prior to hospitalization
  3. Type 1 diabetes mellitus
  4. Systolic blood pressure \<90 mmHg
  5. Expected to newly require treatment with thiazide, tolvaptan, or carperitide within 48 hours of study drug administration
  6. Main cause of acute heart failure hospitalization is not fluid retention (e.g., persistent ventricular tachycardia, persistent atrial fibrillation/atrial flutter with a ventricular response rate of ≥130 bpm, persistent bradycardia with a ventricular response rate of \<45 bpm, an infection, severe anemia, and an acute exacerbation of )
  7. Acute coronary syndrome, pulmonary thromboembolism, or a cerebrovascular accident is the main cause of the present hospitalization.
  8. At risk of ketoacidosis or hyperosmolar hyperglycaemia
  9. On dialysis, including peritoneal dialysis, or the initiation of dialysis during hospitalization is planned
  10. Pregnant or lactating women
  11. Underwent the following therapeutic interventions within 30 days: cardiovascular surgery (e.g., coronary artery bypass grafting, surgery for valvular heart disease, transcatheter aortic valve implantation, percutaneous coronary intervention, percutaneous edge-to-edge mitral valve repair, and other types of surgery at the investigator's discretion) and implantation of an implantable defibrillator, cardiac resynchronization therapy defibrillator, or implantable ventricular-assist device
  12. A diagnosis of acute coronary syndrome, cerebral infarction, or made within 90 days
  13. Ventricular tachycardia with syncope within 90 days
  14. Heart transplant recipient or listed for heart transplantation and expected to undergo transplantation during the present treatment; implanted with an implantable ventricular-assist device or expected to require an implantable ventricular-assist device during the present treatment; or expected to switch to palliative care
  15. Intubated at the time of screening or expected to require intubation within within 48 hours of study drug administration
  16. Severe valvular heart disease expected to be treated with thoracostomy or catheterization (a reason to exclude secondary mitral or tricuspid regurgitation due to reduced cardiac function does not exist, except for the absence of a plan to perform cardiac surgery or therapeutic catheterization)
  17. A diagnosis of secondary cardiomyopathy such as amyloidosis, cardiac sarcoidosis, hemochromatosis, Fabry disease, and muscular dystrophy. Heart failure due to takotsubo cardiomyopathy, obstructive hypertrophic cardiomyopathy, complex congenital heart disease (as determined by the investigator), or pericardial constriction.
  18. A diagnosis of peripartum cardiomyopathy made within 6 months
  19. Active myocarditis
  20. Presence of uncontrolled thyroid disease
  21. Acute cardiac structural abnormalities (e.g., acute mitral regurgitation due to ruptured chordae tendineae)
  22. Symptomatic bradycardia or complete atrioventricular block, being treated with a temporary pacemaker implantation at the time of admission, or expected to require a temporary pacemaker implantation in the future. Patients who have already been treated with a permanent pacemaker implantation do not meet the exclusion criteria.
  23. Serious liver disorder (an increase in , ALT, or ALP level ≥3 times the ) or cirrhosis with varices or other findings suggestive of portal hypertension
  24. Alcohol use disorder of at least mild severity according to the
  25. A diagnosis of active or suspected active malignancy made within 2 years
  26. Coexisting diseases other than heart failure with an expected survival prognosis of ≤1 year
  27. Participation in a clinical study of another drug 30 days before hospitalization
  28. Patients considered to require fasting at screening.
  29. Other conditions likely to interfere with the patient's safety or compliance with the protocol
  30. Other patients who are considered unsuitable by the principal investigator or other investigators
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
444 participants (estimated)

Study arms

  • Experimental
    Empagliflozin

    Patients will be randomized 1:1 to either empagliflozin or placebo.

    Drug: Empagliflozin 10 MG

  • Placebo comparator
    Placebo

    Placebo matching empagliflozin

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. A hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, WHF during hospitalization, and urine output up to 48 hours after treatment initiation, assessed by the win ratio

    WHF, worsening heart failure

    Time frame: Up to 90 days

Secondary outcomes

  1. A hierarchical composite endpoint consisting of death within 90 days, heart failure readmission within 90 days, and WHF during hospitalization

    WHF, worsening heart failure

    Time frame: Up to 90 days

  2. A composite endpoint consisting of WHF during hospitalization, death, heart failure rehospitalization, urgent visit for WHF, intensification of diuretic therapy, and worsening NYHA class within 90 days

    WHF, worsening heart failure

    Time frame: Up to 90 days

  3. Change in NT-proBNP from randomization to 48 hours

    Time frame: Evaluated at 48 hours after randomization

  4. Diuretic response, calculated as urine output achieved by loop diuretics (40 mg intravenous furosemide-equivalent dose) at 48 h after treatment initiation

    Time frame: Evaluated at 48 hours after randomization

  5. Improvement in KCCQ-TSS of ≥5 points from randomization to 30 and 90 days after treatment initiation

    KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire - Total Symptom Score. The scores range from 0 to 100, with 100 being the best possible score.

    Time frame: Up to 90 days

  6. Time to hemodynamic stabilization during index hospitalization

    Time frame: During index hospitalization

  7. Re-worsening of heart failure during index hospitalization

    Time frame: During index hospitalization

  8. Heart failure rehospitalization

    Time frame: Up to 90 days

  9. Death

    Time frame: Up to 90 days

  10. Urine output during the 48 h after randomization

    Time frame: Evaluated at 48 hours after randomization

  11. Cardiovascular death

    Time frame: Up to 90 days

  12. Change in the visual analog scale score for dyspnea from after randomization to 24 and 48 h

    The scores range from 0 to 100, with 100 being the best possible score.

    Time frame: Evaluated at 24 and 48 hours after randomization

  13. Change in high sensitivity cardiac troponin T

    Time frame: Evaluated at 48 hours after randomization

  14. Change in the KCCQ-TSS after randomization to 30 and 90 days

    KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire - Total Symptom Score. The scores range from 0 to 100, with 100 being the best possible score.

    Time frame: Up to 90 days

  15. Composite of renal replacement therapy, renal transplantation, eGFR <15 mL/min/1.73m2, ≥50% decrease in eGFR compared to the first sample or a ≥2-fold increase in creatinine level compared to the first sample within 90 days of randomization

    Time frame: Up to 90 days

  16. Trend in eGFR after randomization to 24 h, 48 h, 30 days, and 90 days

    Time frame: Up to 90 days

  17. Days alive and out of hospital (including those for reasons other than heart failure)

    Time frame: Up to 90 days

07

Study locations

64 of 69 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 51 months is close to that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2022
First posted
May 26, 2022
StartActual
Sep 10, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05392764
Lead sponsor
Juntendo University
Responsible party
Yuya Matsue (Associate Professor, Juntendo University) — Principal investigator
First posted
May 26, 2022
Start date
Sep 10, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Yuya Matsue, MD
Contact
yuya8950@gmail.com
81-3-3813-3111
Yuya Matsue, MD
principal investigator · Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion